Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
An aggregate of human pancreatic β-cells. The red dye indicates cytoplasmic insulin, and the green dye indicates nuclear Pdx-1. Narushima et al. report a reversible immortalization strategy for generating large numbers of functional human β-cells, (p 1274).
Cash-starved biotech companies in Korea are hoping to capitalize on changes to the listing rules for the Korean stock market introduced earlier this year to go public
Chiron's ongoing problems in influenza vaccine production have raised serious questions about the company's future ability to compete in this particular segment of the vaccine market.
An important molecule for growth recently received approval in the US. This approval heralds the first medical application of insulin-like growth factor 1 (IGF-1) as a drug to promote growth in a rare group of very small children.
Under the gun of increased oversight on drug company advertising by the US Food and Drug Administration, the Washington, DC-based industry group Pharmaceutical Research and Manufacturers Association (PhRMA) on 29 July announced a set of guiding principles for ethical practices in direct to consumer advertising (DTC).
A hands-off philosophy based on investing in people has served Jean Deleage well over almost 35 years of venture capital investing in the life sciences. He reflects on biotech investment trends.
Deep-sea prospecting is unveiling bizarre species of microbes that already are providing new sources of industrial enzymes, and could be a source of novel therapeutics. Will the lack of treaties governing activities in international waters compromise the commercial potential of the ocean's largesse? Cormac Sheridan investigates.
Even small biotech companies are taking more control of their product development as cash, competition, and other factors combine to bolster their negotiating power.
A billion nonredundant molecular interactions lie buried in the biomedical literature. A text-mining approach could help scientists better exploit this knowledge.
Reduced side effects and more effective therapies are some of the benefits promised by pharmacogenomics. But to reach these goals, industry will have to marshal a broad range of skills.
